Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Consistent with the base-case analysis, sensitivity analyses demonstrated that using GLP-1RAs versus insulin was either cost-saving or cost-effective, except for the analyses where the treatment effectiveness was estimated based on the AT scenario in the second and third sensitivity analyses, showing that a GLP-1RA versus insulin therapy was not cost-effective for averting one case of all-cause death from the payer perspective
Proc Natl Acad Sci U S A 104:1933319338 Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA (2002) Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose
This product is not a drug and has not been approved by the U.S
Providers advise birth control for individuals of childbearing potential while using GLP-1 agonists (48)
US$ 23.69
US$ 23.44
US$ 25.40
US$ 23.26
US$ 25.76
US$ 26.82
US$ 20.62
